{
  "pmcid": "12131451",
  "sha256": "c25fbdff2613edefa72cbde8467017345f3a4a317086f53a64d9a72748a00758",
  "timestamp_utc": "2025-11-09T23:27:34.997963+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.166231282698899,
    "reading_ease": 33.66927476095981,
    "word_count": 241
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Neostigmine Reversal in Elderly Patients Undergoing Laparoscopic Pancreaticoduodenectomy"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "single-center randomised controlled trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "Elderly patients (≥65 years) undergoing elective LPD with cis-atracurium"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to receive neostigmine reversal or no reversal"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate the effect of neostigmine reversal on postoperative atelectasis and other complications"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the incidence of atelectasis within the first 3 postoperative days"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated sequence with allocation concealment via sealed envelopes"
      },
      "Blinding": {
        "score": 1,
        "evidence": "Outcome assessors were blinded to group allocation"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 501 patients were randomised: 89 to the neostigmine group and 213 to the control group"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis was conducted on 302 patients using an intention-to-treat approach"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Neostigmine reversal was associated with a lower incidence of atelectasis (OR 0.43, 95% CI 0.24–0.75, p = 0.003)"
      },
      "Harms": {
        "score": 1,
        "evidence": "No significant adverse events were reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: [2022]285."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 19,
    "max_score": 25
  }
}